Arrowhead Pharmaceuticals (ARWR) Shares Outstanding (2010 - 2026)

Arrowhead Pharmaceuticals' Shares Outstanding (Entity) history runs 15 years deep, the most recent figure standing at $138.1 million for Q1 2025.

• Quarterly Shares Outstanding (Entity) rose 11.22% year-over-year to $138.1 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $138.1 million (up 11.22% YoY) and the FY2024 annual result came in at $124.4 million, up 15.9% from the prior year.
• Shares Outstanding (Entity) was $138.1 million for Q1 2025 at Arrowhead Pharmaceuticals, up from $125.6 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $138.1 million in Q1 2025 and bottomed at $104.0 million in Q1 2021.
• A 5-year average of $112.1 million and a median of $106.9 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) gained 1.1% — and 2024, when it grew 16.81%.
• Arrowhead Pharmaceuticals' Shares Outstanding (Entity) stood at $104.8 million in 2021, then advanced by 1.28% to $106.1 million in 2022, then increased by 1.28% to $107.5 million in 2023, then rose by 16.81% to $125.6 million in 2024, then advanced by 9.95% to $138.1 million in 2025.
• Business Quant data shows ARWR's Shares Outstanding (Entity) at $138.1 million in Q1 2025, $125.6 million in Q4 2024, and $124.4 million in Q3 2024.